SIMADEN 40 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

simaden 40 mg tabletti, kalvopäällysteinen

hexal a/s - simvastatinum - tabletti, kalvopäällysteinen - 40 mg - simvastatiini

SIMADEN 80 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

simaden 80 mg tabletti, kalvopäällysteinen

hexal a/s - simvastatinum - tabletti, kalvopäällysteinen - 80 mg - simvastatiini

SIMADEN 60 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

simaden 60 mg tabletti, kalvopäällysteinen

hexal a/s - simvastatinum - tabletti, kalvopäällysteinen - 60 mg - simvastatiini

Hydrocortisone aceponate Ecuphar (previously Cortacare) Euroopan unioni - suomi - EMA (European Medicines Agency)

hydrocortisone aceponate ecuphar (previously cortacare)

ecuphar - hydrokortisoniaseskonaatti - kortikosteroidit, dermatologiset valmisteet - koirat - tulehduksellisten ja kutinaisten dermatoosien oireenmukaiseen hoitoon koirilla. for alleviation of clinical signs associated with atopic dermatitis in dogs.

Pyrukynd Euroopan unioni - suomi - EMA (European Medicines Agency)

pyrukynd

agios netherlands b.v. - mitapivat sulfate - genetic diseases, inborn; anemia, hemolytic - other hematological agents - pyrukynd is indicated for the treatment of pyruvate kinase deficiency (pk deficiency) in adult patients (see section 4.

Tibsovo Euroopan unioni - suomi - EMA (European Medicines Agency)

tibsovo

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastiset aineet - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.

Paxlovid Euroopan unioni - suomi - EMA (European Medicines Agency)

paxlovid

pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.